Aurinia Pharmaceuticals Inc. (AUPH) AI Stock Analysis

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company engaged in commercial-stage development of therapies for diseases with significant unmet medical needs across the United States. Its central portfolio asset is LUPKYNIS, a therapy created for adult patients with active lupus nephritis, a serious kidney condition. Aurinia also maintains a strategic collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. to expand its therapeutic reach globally. Headquartered in Victoria, British Columbia, Canada, the company leverages regional research and development resources to support its biopharmaceutical pipeline.

Aurinia increased its annual revenue from $45.6M in FY2021 to $283.1M in FY2025, posting a 5-year revenue CAGR of 41.4% through FY2025. Gross margin stood at 88.5% in FY2025, while operating margin expanded to 37.1% from -2.0% in FY2024. Net income reached $287.2M in FY2025, reflecting a net margin of 101.5% and EPS of $0.81. For the trailing twelve months ending June 30, 2026, revenue totaled $311.5M with an operating margin of 55.7% and EPS of $2.28. In the quarter ended June 30, 2026, revenue increased 18.9% year-over-year, and earnings increased 75.5%.

As of June 30, 2026, Aurinia held $443.1M in cash and short-term investments against $60.4M in total debt, resulting in a net cash position of $382.7M. The current ratio stood at 5.42 and the debt-to-equity ratio was 0.10. Operating cash flow reached $135.7M in FY2025, yielding free cash flow of $135.4M after capital expenditures of $252,000. During FY2025, the company deployed $98.2M toward share buybacks, while the share count rose 1.1% over five years.

Aurinia trades at a trailing P/E of 7.2x and a forward P/E of 11.8x, compared to the median of its US-listed Healthcare peers of 24.6x and 17.3x, respectively. Its enterprise value-to-EBITDA is 10.0x, below the peer median of 12.0x, though its price-to-sales multiple of 7.1x exceeds the peer median of 4.1x. Over the past year, the stock returned 42.9%, outperforming the S&P 500 return of 16.8%. Over a 5-year period, the stock declined 19.7% while the S&P 500 gained 83.0%.

Wall Street coverage includes 5 Strong Buy and 2 Hold ratings, with no Buy, Sell, or Strong Sell recommendations. The mean price target of $17.86 implies an upside of 8.2% relative to the last close of $16.51. For the fiscal year ending December 31, 2026, analysts estimate revenue of $329.1M and EPS of $0.94, representing a 54.4% earnings reduction. Aurinia exceeded EPS expectations in each of the last 4 quarters, and its next earnings release is scheduled for November 3, 2026.

This page is an AI-written research summary of Aurinia Pharmaceuticals Inc. (AUPH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AUPH income statement, AUPH balance sheet, AUPH key metrics, AUPH analyst forecast, AUPH chart. See the AUPH stock overview for the latest quote and news.